GENOVA Inc. AI Stock Analysis
Want to see JP:9341 full AI Analyst Report?
GENOVA Inc. (9341) AI Stock Analysis
GENOVA Inc.
(TSE/TYO:9341)
The score is held back primarily by weakened 2026 fundamentals—sharp margin/ROE compression and a major deterioration in cash generation with negative free cash flow—despite strong revenue growth and modest leverage. Technicals are modestly supportive with price above key longer-term averages, and valuation is a relative strength given the solid dividend yield and reasonable P/E.
GENOVA Inc. (9341) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 9.93B
- Dividend Yield
- 5.24%
- Average Volume (3M)
- 63.77K
- Price to Earnings (P/E)
- 15.6
- Beta (1Y)
- 0.67
- Revenue Growth
- 46.39%
- EPS Growth
- 12.53%
- Country
- Japan
- Employees
- 529
- Sector
- General
- Sector Strength
- 55
- Industry
- Software - Application
GENOVA Inc. Business Overview & Revenue Model
Company Description
Operating within Japan, GENOVA, Inc. focuses on the digital healthcare market, providing both medical platform services and smart clinic solutions. Its offerings include Medical Doc, a comprehensive online platform that distributes diverse content, s...
GENOVA Inc. Financial Statement Overview
Summary
Strong 2026 revenue growth (~24%) is a clear positive, and leverage remains modest. However, profitability deteriorated sharply with meaningful margin compression and a large decline in ROE, while cash conversion weakened significantly with very low operating cash flow relative to net income and negative free cash flow in 2026—pressuring overall financial quality.
Income Statement
58NeutralBalance Sheet
76PositiveCash Flow
34Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.77B | 11.57B | 10.01B | 8.68B | 6.51B | 4.80B |
| Gross Profit | 6.76B | 6.47B | 7.38B | 6.55B | 4.79B | 3.50B |
| EBITDA | 513.44M | 543.85M | 2.11B | 2.38B | 1.79B | 1.09B |
| Net Income | 623.48M | 275.40M | 1.41B | 1.73B | 1.26B | 686.27M |
Balance Sheet | ||||||
| Total Assets | 11.31B | 10.26B | 8.53B | 8.20B | 5.41B | 2.82B |
| Cash, Cash Equivalents and Short-Term Investments | 5.08B | 5.32B | 5.87B | 5.97B | 3.86B | 1.65B |
| Total Debt | 1.77B | 735.71M | 20.84M | 377.78M | 28.25M | 163.50M |
| Total Liabilities | 5.16B | 3.36B | 1.53B | 2.16B | 1.37B | 1.33B |
| Stockholders Equity | 6.15B | 6.90B | 7.00B | 6.04B | 4.04B | 1.49B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -46.98M | 1.06B | 1.77B | 1.11B | 513.36M |
| Operating Cash Flow | 0 | 53.85M | 1.19B | 1.82B | 1.20B | 623.77M |
| Investing Cash Flow | 0 | -809.75M | -275.93M | -94.24M | -113.45M | -179.06M |
| Financing Cash Flow | 0 | 199.63M | -1.01B | 376.82M | 1.13B | 59.88M |
GENOVA Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9341, the sentiment is Negative. The current price of 573.00 is below the 20-day moving average (MA) of 588.05, below the 50-day MA of 604.20, and below the 200-day MA of 588.95, indicating a bearish trend. The MACD of -9.73 indicates Positive momentum. The RSI at 41.88 is Neutral, neither overbought nor oversold. The STOCH value of 60.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9341.
GENOVA Inc. Peers Comparison
Overall Rating
JP:921867.8Neutral
JP:934161Neutral
JP:443854Neutral
JP:448054Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 68Neutral | JPY 7.73B | 30.81 | ― | 1.36% | 34.18% | -32.29% | |
| 61Neutral | JPY 10.22B | 15.55 | ― | 5.24% | 46.39% | 12.53% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | JPY 2.34B | -4.31 | ― | ― | 14.84% | 30.67% | |
| 54Neutral | JPY 67.05B | 35.67 | 11.30% | ― | 21.01% | 10.15% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:9341 | GENOVA Inc. | 573.00 | 10.50 | 1.87% | |
| JP:4480 | Medley, Inc. | 2108.00 | -447.00 | -17.50% | |
| JP:4438 | Welby Inc. | 274.00 | -57.00 | -17.22% | |
| JP:9218 | Mental Health Technologies Co. Ltd. | 736.00 | -82.54 | -10.08% | |
| JP:366A | Wellness Communications Corporation | 1100.00 | -135.96 | -11.00% |
GENOVA Inc. Corporate Events
GENOVA Acquires “Karada ni Iikoto” Healthcare Media Business to Boost Medical Platform
GENOVA Inc. has agreed to acquire the “Karada ni Iikoto” healthcare media business from Central Medience Co., Ltd. for an expected 51 million yen in cash, obtaining contracted editorial services, sponsored content, and PR functions centered on the pl...
Genova Returns to Profit as Sales Surge and New Subsidiary Added
Genova Inc. reported a sharp 64.7% year-on-year increase in net sales to ¥3.06 billion for the quarter ended June 30, 2026, while operating and ordinary losses narrowed compared with the prior-year period, resulting in profit attributable to owners o...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026
